title: [Intravascular lymphoma revealed by generalized arborescent telangiectasia and repeated venous thrombosis].
abstract: BACKGROUND
  Intravascular lymphoma is a rare form of non-Hodgkin's lymphoma characterized by proliferation of lymphoid cells within the lumen of small veins, small arteries and capillaries.
  
  
  METHODS
  A 79-year-old man presented with repeated superficial venous thrombosis of the lower limbs associated with diffuse telangiectasia of the trunk, upper arms and thighs but with normal epidermis. Screening for thrombophilia and neoplasm were negative. The patient subsequently developed abdominal pain, lower-limb oedema, deterioration in performance status and rapidly increasing telangiectasia with the appearance of generalized oedematous cutaneous induration. Increased LDH and anaemia were observed without other blood count anomalies. Intravascular lymphoma was diagnosed on a skin biopsy with telangiectasia and oedema. After eight courses of treatment with rituximab-CHOP the outcome was good.
  
  
  CONCLUSIONS
  A few telangiectasias associated with nodules or infiltrated plaques are often a clinical manifestation of intravascular lymphoma. The dermatological presentation described here is interesting for two reasons: on the one hand, telangiectasias were initially isolated in normal epidermis without any infiltration for more than one year and, on the other hand, the skin infiltration seen subsequently was very extensive and marked. Moreover, although microthrombi are frequent in small and medium-sized blood vessels, thrombosis of large vessels is rarely described in intravascular lymphoma.
authors.affiliation: Clinique de dermatologie, hôpital Claude-Huriez, CHRU de Lille, Lille, France. s-vercambre@chru-lille.fr
authors.forename: S
authors.initials: S
authors.lastname: Vercambre-Darras
authors.forename: L
authors.initials: L
authors.lastname: Mortier
authors.forename: M
authors.initials: M
authors.lastname: Lambert
authors.forename: C
authors.initials: C
authors.lastname: Delattre
authors.forename: V
authors.initials: V
authors.lastname: Gaxotte
authors.forename: S
authors.initials: S
authors.lastname: Morell-Dubois
authors.forename: J
authors.initials: J
authors.lastname: Paccou
authors.forename: L
authors.initials: L
authors.lastname: Terriou
authors.forename: F
authors.initials: F
authors.lastname: Morschhauser
authors.forename: F
authors.initials: F
authors.lastname: Piette
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D012871:Skin Diseases / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D013684:Telangiectasis / Q000175:diagnosis* / Q000209:etiology; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone